Bioadaptives, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
OID
BioAdaptives Inc. announces successful completion of Zeranovia dosage trials, demonstrating significant weight loss with minimal side effects.
OID
8-K: BioAdaptives Bolsters Leadership with Key Appointments to Board of Directors and Advisory Board
BioAdaptives, Inc. announces the appointment of Mark Frissora to its Board of Directors and Reed Harris to its Advisory Board, aiming to leverage their expertise for strategic growth.
OID
BioAdaptives, Inc. has declared a one-for-one stock dividend for all common shareholders, with a record date projected for the second week of January 2025.
OID
BioAdaptives, Inc. has announced the approval of a human clinical trial for its weight management product, Zeranovia, by an Institutional Review Board.
OID
BioAdaptives has completed a 1-for-300 reverse stock split to reduce outstanding shares and increase the stock price, effective November 21, 2024.
OID
BioAdaptives, Inc. disclosed an upcoming reverse stock split after a draft shareholder letter was prematurely released online due to a website error, causing market confusion.
OID
BioAdaptives, Inc. has appointed James Keener as its new CEO and Chairman of the Board, following the resignations of Edward Jacobs and Robert Ellis.
OID
BioAdaptives Inc. has dismissed BF Borgers as its auditor after the firm was suspended by the SEC and appointed Boladale Lawal & Co as its new independent auditor.